Abstract
Chronic myelogenous leukemia is characterized by the reciprocal chromosomal translocation (9;22), which generates a novel fusion gene, BCR-ABL. Bcr-Abl-expressing leukemia cells are highly resistant to apoptosis. Imatinib an Abl kinase inhibitor, is a highly effective agent for patients with CML. However, a small percentage of these patients and most advanced-phase patients relapse on imatinib therapy. It is poorly understood whether the Abl kinase inhibitors are able to eradicate CML progenitor or stem cells. In this study, we investigated the role of HOXA10 in CML cell lines and the hematopoietic progenitor cells derived from CML patients, and whether the regulation of HOXA10 eradicates Bcr-Abl(+) hematopoietic stem/progenitor cells. The Abl kinase inhibitors and PI3K inhibitor, LY294002, induced the expression of HOXA10, and it enhanced apoptosis in CML cells. Moreover, the reduction of HOXA10 expression by siRNA in CML cells inhibited apoptosis by treatment with the Abl kinase inhibitors and LY294002. These results revealed that HOXA10 had an important role in induction of apoptosis by the Abl kinase inhibitors in CML cells. Finally, we showed that the inhibition of HOXA10 expression by siRNA increased the numbers of CFU-GE...Continue Reading
References
Feb 16, 1990·Science·G Q DaleyD Baltimore
Mar 2, 1990·Science·T G LugoO N Witte
Jan 1, 1989·Genome Génome / Conseil National De Recherches Canada·E BoncinelliA Simeone
Jun 13, 1985·Nature·E ShtivelmanE Canaani
Oct 13, 1988·The New England Journal of Medicine·R KurzrockM Talpaz
Dec 6, 1994·Proceedings of the National Academy of Sciences of the United States of America·G SauvageauR K Humphries
May 1, 1996·Stem Cells·H J LawrenceC Largman
Jan 1, 1997·Molecular and Cellular Biology·U ThorsteinsdottirR K Humphries
Nov 20, 1997·Journal of Cellular Physiology·M C MagliH J Lawrence
Oct 21, 2000·Genes & Development·V C Bromleigh, L P Freedman
Oct 25, 2000·Molecular and Cellular Biology·M SalehM S Featherstone
Apr 5, 2001·The New England Journal of Medicine·B J DrukerM Talpaz
Apr 6, 2001·Blood·C BuskeR K Humphries
Nov 24, 2001·Blood·J M BjörnssonS Karlsson
Feb 7, 2002·Blood·Tom TaghonGeorges Leclercq
Mar 6, 2002·Blood·Moshe TalpazCharles L Sawyers
Aug 20, 2002·Oncogene·Agata KlejmanTomasz Skorski
Feb 20, 2003·Leukemia·M StanglmaierM Hallek
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Mar 15, 2003·The New England Journal of Medicine·Karl Peggs, Stephen Mackinnon
Sep 13, 2003·Blood·Kerol BartolovicTim H Brümmendorf
Jun 5, 1964·Science·C T RUDKINP C NOWELL
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Feb 16, 2005·Cancer Cell·Ellen WeisbergJames D Griffin
Apr 19, 2005·Cancer Research·Enrique J AndreuIgnacio Pérez-Roger
Jun 3, 2005·Cancer Research·Thomas O'HareBrian J Druker
Jul 1, 2005·Nature·Franziska MichorMartin A Nowak
Citations
Mar 14, 2012·Carcinogenesis·Kazuhiro SentaniWataru Yasui
Feb 7, 2013·BMC Cancer·Cesarina GiallongoFrancesco Di Raimondo
May 18, 2012·Journal of Translational Medicine·Hiroko NatsumeHaruhiko Sugimura
Feb 25, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Faman XiaoLinlang Guo
Jan 25, 2019·Journal of Virology·Qingyu YangJianguo Wu
May 1, 2009·Expert Review of Endocrinology & Metabolism·Lorenzo IughettiAntonino Forabosco
Nov 1, 2017·Oncology Letters·Lu-Yan ShenKe-Neng Chen
Dec 14, 2018·Molecular Cancer·Ming ShaoXianping Lv
Dec 11, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Lan YuanRongxing Jiang